Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q1 FY2026 Earnings Presentation
92 slides from Jubilant Pharmova's earnings presentation, Jul 29, 2025
Slide 1: Cover letter to stock exchanges
July 29, 2025 BSE Limited, National Stock Exchange of India Limited, Floor 25, P. J. Towers Exchange Plaza, Bandra-Kurla Complex, Dalal Street, Fort Bandra (E), Mumbai - 400 001 Mumbai - 400051 Scrip Code: 530019 Symbol: JUBLPHARMA Sub: Press Release alongwith Earnings Presentation on the financials
Slide 2: Jubilant Pharmova – Q1'FY26 Results press release
Jubilant Pharmova Limited 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 PRESS RELEASE www.jubilantpharmova.com Noida, Jul 29, 2025 JUBILANT PHARMOVA – Q1’ FY26 RESULTS On track towards Vision 2030 Solid growth momentum along with EBITDA & PAT margin expansion Strong customer traction i
Slide 3: Q1'FY26 Financial Highlights
Q1’FY26 Financial Highlights In Q1’FY26, Revenue grew by 10% on a YoY basis to Rs. 1,901 Cr. on the back of growth in revenue across all business units. EBITDA grew by 14% on a YoY basis to Rs. 302 Cr. due to improved performance in CRDMO and Generics. Q1’FY26 normalised PAT increased by 48% on a Yo
Slide 4: About Jubilant Pharmova Limited
CRDMO – Indian leader for integrated drug discovery & formidable API player In Q1’FY26, the Drug Discovery business revenue grew by 42% to Rs. 161 Cr. EBITDA grew by 46% to Rs. 32 Cr. Revenue continue to increase due to increase in revenue from large Pharma customers. We have integrated new R&D faci
Slide 5: For more information, please contact / Disclaimer
disorders. The Company operates multiple manufacturing facilities that cater to all the regulated markets including USA, Europe and other geographies. Jubilant Pharmova Limited has a team of around 5,500 multicultural people across the globe. The Company is well recognised as a ‘Partner of Choice’ b
Slide 6: Earnings Presentation Q1'FY26
Earnings Presentation Q1’FY26
Slide 7: Disclaimer
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product
Slide 8: Strong presence in diverse sectors
Strong presence in diverse sectors • Pharmaceuticals • Contract Research & Development Services • Life Science Ingredients • Therapeutics • Performance Polymers • Auto Dealerships • Food Service (QSR) • Oil and Gas services Global presence through investments • India • Europe • Africa • USA • Singap
Slide 9: Business units overview
Radiopharma Allergy Immunotherapy CDMO Sterile Injectables Leading manufacturer 2nd largest player Leading contract manufacturer of Radiopharmaceuticals in the US Allergenic extract market in North America in North America Sole supplier of Venom Serves top global innovator pharma 2nd largest radioph
Slide 10: Business wise and currency wise revenue split
Business wise Revenue Split Currency wise Revenue Split Q1’FY26 Q1’FY26 Generics, 9% Rest, 7% Allergy Immunotherapy, 10% CRDMO, Radiopharma, 16% 46% CDMO - SI, USD, 93% 19% Specialty Products (Radiopharma, Allergy Immunotherapy) and Specialty Services (CDMO & CRDMO) Majority revenues are contribute
Slide 11: Geography wise revenue split
Geography wise Revenue Split Origin of Goods & Services sold in the US Q1’FY26 Q1’FY26 Goods & Services from India, Rest of 15%* World, 21% Goods & Services from Canada, 17%* Goods & Services USA, 79% from US , 68% US market constitutes Goods from Canada (Radiopharmaceuticals) exempted from majority
Slide 12: Manufacturing and research facilities
Kirkland, Montreal, Canada Spokane, Washington, US CDMO – SteriIe Injectables Radiopharmaceuticals CDMO – SteriIe Injectables Allergy Immunotherapy NORTH AMERICA 6 Manufacturing facilities Roorkee, Uttrakhand, India - Generics Nanjangud, Karnataka, India - CDMO API 3 INDIA Research facilities & EURO
Slide 13: Vision 2030: 2x Revenue, 25% EBITDA Margin, Zero Net Debt
From To Actual FY24 FY30 Trailing 12 Months 2x Revenue Rs. 6,703 Cr. Rs. 13,500 Cr. Rs. 7,404 Cr. 25% EBITDA Margin ~ 15 % 23% to 25% 17% Rs. 1,535 Cr. Zero Net Debt Rs. 2,457 Cr. Zero End of Q1’FY26 12%* High Teens RoCE High Single digit High Teens Q1’FY26 Annualised • ( EBIT before exceptional ite
Slide 14: Business Growth Drivers
Business Growth Drivers Leadership in Ruby-Fill® Radiopharma Launch New PET, SPECT and Therapeutic products (MIBG) Invest in 6 high margin PET Radiopharmacies in US Allergy immunotherapy Strengthen competitive position and develop new products CDMO - Sterile Injectables Double capacity in Spokane, U
Slide 15: Radiopharma
Radiopharma
Slide 16: Radiopharmaceuticals have a growing role in treatment of life-threatening diseases
SPECT PET Radiopharmaceutical Imaging Imaging Therapeutics Low Energy High Energy Systemically or Locally gamma rays positrons Delivered detected by SPECT cameras detected by a PET scanner radiation using pharmaceuticals Isotopes - Tc99m Isotopes - Rb82, F18, Ga68 Isotopes – I131, Lu177, Ac225 MAA,
Slide 17: US Radiopharmaceutical Market Growth Drivers & Trends
US Radiopharmaceutical Market Growth Drivers & Trends USD Bn. ~ 20 Launch of advanced • PSMA Therapeutic, Pluvicto for Prostrate Cancer ~USD 2.0 Bn. Therapies CAGR: New • PSMA Diagnostics for Prostrate Cancer ~ USD 1.5 Bn. 20%+ • Broad range of applicability e.g. Alzheimer’s products in • Special re
Slide 18: Manufacturing, logistics and regulatory barriers
Stringent manufacturing & regulatory environment Adherence with extensive license framework. Stringent manufacturing set up required to handle isotopes Managing time sensitive Forward integration logistics with radiopharmacies Radioactive isotope decays Forward integration with exponentially. The ha
Slide 19: Radiopharmaceuticals product portfolio
Organ Key Indication Product PET Dx Cardiac Coronary Artery disease Ruby - Fill® Breast Lymph nodes detection Sulfur Colloid Cardiac blood pool imaging Tc99m-Gluceptate Cardiac • Diversified across diagnostics & therapeutics Coronary Artery Disease Tc99m-Sestamibi • Current TAM at USD 400 Mn. Gastro
Slide 20: Key products: MAA, DTPA, Ruby-Fill, HICON
Draximage ® MAA Draximage ® DTPA Ruby-Fill ® HICON® Sodium Iodine I 131 Solution USP It is used for Cardiac PET scan, MAA is used in the perfusion DTPA is used to assess HICON® is a radioactive to evaluate regional myocardial phase of a ventilation/perfusion pulmonary ventilation function in therape
Slide 21: Radiopharmaceuticals quarterly results
Particulars ( Rs. Cr.) Q1’FY25 Q4’FY25 Q1’FY26 Y-o-Y • Q1’FY26 revenue grew on back of growth in Ruby-Fill ® and Sulfur Colloid Revenue 262 296 271 3% • Q1’FY26 EBITDA stable YoY EBITDA 126 136 126 0% EBITDA Margin (%) 48% 46% 46% (150) bps 16
Slide 22: Radiopharmaceuticals FY30 targets
Revenue: Growth & Margins to improve on the back More than 2x of FY24 of new products introduction EBITDA Margin: More than 50% Growth drivers: • Ruby-Fill® Revenue: Rs. 1,083 Cr. EBITDA Margin: 47% Revenue: Rs. 1,074 Cr. • New PET & EBITDA Margin: 47% SPECT products Revenue: Rs. 952 Cr. EBITDA Marg
Slide 23: Ruby-Fill Rubidium generator and Elusion System
Ruby-Fill ® Rubidium 82 generator and Elusion System Growth drivers: Competitive advantage • Ruby-Fill® • Longer life per generator (7 weeks vs 6 weeks for peer) • New PET & SPECT • Better image quality and consistency products • Constant Activity • MIBG Current Position • Market Size ~ USD 180 Mn.
Slide 24: New products in SPECT and PET imaging
Developing new products in SPECT Imaging to maintain leadership & in PET Imaging for growth Growth drivers: • Ruby-Fill® Incremental TAM Potential Peak Annual Timeline No. of launches • New PET & SPECT USD Mn. Sales - USD Mn. products FY27 50 20 2 • MIBG FY28 250 60 3 FY29 250 40 4 Total 550 120 9 1
Slide 25: HICON and MIBG
HICON® Sodium Iodide I 131 - Commercialised MIBG - Undergoing Clinical trials Growth drivers: • Ruby-Fill® • Potential peak sales • New PET & SPECT USD 70 - 100 Mn. products • Data package to FDA • MIBG by H2’FY26 • Iodine I 131, HICON® is standard care for patients • Used in imaging & treatment for
Slide 26: Radiopharmacy
m \sm 93 | oa \ os \ a \8 Vp \ Pu \ Am \Gm \ 8 \eptunium, ae \ Americium \ Cuwurn | Barkan |\Cadon
Slide 27: Radiopharmacy Growth Drivers & Trends
Growth Drivers & Trends SPECT Radiopharmacy PET Radiopharmacy • Consolidated market in the US. Large M&A transactions in Radiopharmacies • Increasing demand for novel PET products driving PET radiopharmacies growth • Stringent USP 825 regulations to drive increase in therapeutics dispensing through
Slide 28: Consolidated market and barriers to entry
Consolidated Market Barriers to Entry 1 Stringent Regulations # of radio SPECT PET # of hospitals Each treatment site is required to obtain a license pharmacies in the US pharmacies pharmacies served in the US from Nuclear Regulatory Commission and comply with additional state, local, and hospital r
Slide 29: Radiopharmacy network map
nd 45 Current SPECT Current Cyclotron 6 New PET SITES Radiopharmacies USP<825> JDR network is USP 825 with ~ 20% WD compliant Portland volume market MT ND ME share OR MN VT ID Saginaw NH SD WI NY Business moat 1,800 Minneapolis Boston Detroit Wilkes WY MI Barre Phila- RI Unique combination of delphi
Slide 30: Radiopharmacy quarterly results
Particulars ( Rs. Cr.) Q1’FY25 Q4’FY25 Q1’FY26 Y-o-Y • Q1’FY26 revenue grew YoY on the back of increase in volume from new PET products Revenue 570 600 598 5% • Q1’FY26 EBITDA lower YoY due to increase in competitive intensity in SPECT radiopharmacies EBITDA 13 6 10 (22%) EBITDA Margin (%) 2% 1% 2%
Slide 31: Radiopharmacy FY30 targets
Revenue: Growth on track 2x of FY24 Margins to improve as PET Pharmacy EBITDA Margin: revenues increase ~ 7% to 8% Revenue: Rs. 2,342 Cr. Revenue: Rs. 2,314 Cr. EBITDA Margin: 1% EBITDA Margin: 1% Revenue: Rs. 2,050 Cr. EBITDA Margin: 3% FY24 FY25 TTM FY30 26
Slide 32: PET radiopharmacy expansion
Growth driver: • PET expansion • Strengthened network to enable long term contracts with PET radiopharmaceutical manufacturers • Fully operational by FY28. Funding through internal accruals and long-term credit • Expect Asset turnover of 1.0x and RoCE 20% + on the USD 50 Mn. investment Continue to i
Slide 33: Allergy Immunotherapy
Allergy Immunotherapy
Slide 34: Allergies, testing and treatment
• 20% + global population have allergies e.g. Asthma and Allergenic Rhinits • Allergy Immunotherapy requires repeated shots of allergic antigens to develop immunity Allergies Testing Treatment 29
Slide 35: Global Allergy Immunotherapy Market
Global Allergy Immunotherapy Market Growth Drivers and Trends USD Bn. • Concentrated US market with 3 players 3.0 • Complex supply chain from sourcing to processing 2.2 2.7 • Grandfathered approvals, new product needs BLA 2.0 0.2 0.3 • Market increasing in Sub-Lingual delivery 2023 2028 Non-US US •
Slide 36: HollisterStier brand and extracts
nd • 100-year-old ‘HollisterStier’ brand • Onshore US FDA approved manufacturing • Sole Supplier of Venom extracts in the US • Dedicated sales force in the US • 200+ allergenic & 6 venom extracts • 2,000+ Allergists / ENTs as customers Venom Extracts Allergenic Extracts Skin Testing Devices Venom ex
Slide 37: Allergy Immunotherapy quarterly results
• Q1’FY26 revenue grew on the back of revenue Particulars ( Rs. Cr.) Q1’FY25 Q4’FY25 Q1’FY26 Y-o-Y growth in the US market Revenue 168 192 181 8% • Q1’FY26 EBITDA stable YoY. EBITDA margins in the normalized range EBITDA 63 88 63 (1%) EBITDA Margin (%) 38% 46% 35% (300) bps 32
Slide 38: Allergy Immunotherapy FY30 targets
Revenue: Growth & Margins on track ~1.5x of FY24 EBITDA Margin: 35% to 40% Revenue: Rs. 714 Cr. Revenue: Rs. 701 Cr. EBITDA Margin: 34% Revenue: Rs. 679 Cr. EBITDA Margin: 35% EBITDA Margin: 40% FY24 FY25 TTM FY30 33
Slide 39: Allergy Immunotherapy growth strategy
Strengthen competitive Grow outside US Increase investment position in US business in R&D • Retain and grow Venom • Develop new products & customers & patient base • Increase outside US technologies Venom sales through strategic partnerships in • Increase US revenue in • Build treatment European mar
Slide 40: CDMO - Sterile Injectables
— aR Ce = ta >} CDMO - Sterile. Injectables
Slide 41: CDMO-SI Growth Drivers & Trends
Global CDMO-SI Market Size Growth Drivers & Trends USD Bn 20 • Innovator Pharma companies, for their US 17 16 requirement, are planning to shift the 14 13 manufacturing from Europe to US, as a risk mitigation measure due to impending Tariffs by the US Govt. • Consolidation in supply due to large 202
Slide 42: Contract duration and barriers in CDMO-SI
• Majority of commercial contracts are typically long duration (typically 3 years or more with auto renewal) • Greenfield expansion is considerably difficult due to high up-front capex required with ongoing opex to support initial product commercialization • Innovator companies prefer onshore North
Slide 43: Top pharma customers and fill-finish services
• 5 of the top 20 pharma companies as customers • 25+ customers across the world with multiple products having patent protection and limited competition • 5+ years average relationship time with Top 10 Customers • 90%+ repeat customer business • 24 months of switching timelines for customers • Full
Slide 44: CDMO Sterile Injectables quarterly results
• Q1’FY26 revenue grew YoY due to increase in Particulars ( Rs. Cr.) Q1’FY25 Q4’FY25 Q1’FY26 Y-o-Y sales volume Revenue 324 340 370 14% • Q1’FY26 EBITDA increased YoY, EBITDA margins lower QoQ due to annual maintenance EBITDA 57 95 62 9% shutdown at Spokane facility EBITDA Margin (%) 18% 28% 17% (90
Slide 45: CDMO-SI FY30 targets
Revenue : More than 2x of FY24 EBITDA Margin : Growth ahead of expectations More than 25% Margins on track Revenue : Rs. 1,318 Cr. EBITDA Margin : 23% Revenue : Rs. 1,272 Cr. EBITDA Margin : 23% Revenue : Rs. 1,117 Cr. EBITDA Margin : 17% FY24 FY25 TTM FY30 40
Slide 46: Spokane capacity expansion timeline
Growth driver: • Doubling Capacity Timeline FY’24 FY’25 FY’26 FY’27 FY’28 LINE 3 Installation Media Fill Tech Transfer Commercial Production LINE 4 Design Construction Installation Media Fill Commercial Production • Total investment at USD 285 Mn. ( RoCE > 20%) including US Govt. funding of USD 150
Slide 47: CRDMO: Drug Discovery Services, CDMO API
CRDMO: Drug Discovery Services, CDMO API
Slide 48: CRDMO Growth Drivers & Trends
Drug Discovery Services Market Size USD Bn. Growth Drivers & Trends 10 8 Drug Discovery Market • Biosecure Act advantage • Rise in specialized technologies such as ADCs and oligonucleotides 2023 2028 CDMO API Market Size USD Bn. CDMO API Market 130 95 • Rising interest in custom generics • Rapid mom
Slide 49: Large pharma customers in Drug Discovery
• 8 of the top 20 pharma companies as customers with 5x increase in revenue share from Large Pharma • Indian Leader for “Integrated Drug Discovery”, with a track record of +85 programs and Big pharma strategic partnership • Strengthen European penetration, with multifold revenue increase • Fully int
Slide 50: Drug Discovery Services and CDMO capabilities
Drug Discovery Services & Early CDMO Late CDMO & APIs Integrated Chemistry Research Contract Development & Advanced Intermediate CoE Biologics Drug Discovery Centre Innovation Centre Manufacturing Centre & ( St. Julien, France ) (IDDC, Bengaluru) (CIRC, G. Noida) (API CDMC) API Manufacturing ~ 35 Sc
Slide 51: Drug Discovery Services quarterly results
Particulars ( Rs. Cr.) Q1’FY25 Q4’FY25 Q1’FY26 Y-o-Y • Q1’FY26 revenue increased YoY from scaling Large Pharma contracts Revenue 113 156 161 42% • Q1’FY26 EBITDA increased YoY, EBITDA margins lower QoQ due to change in project mix EBITDA 22 41 32 46% and investment in business development EBITDA Mar
Slide 52: Drug Discovery FY30 targets
Revenue: ~ 3x of FY24 EBITDA Margin: On track to reach our Vision 2030 aided by More than 25% Large Pharma strategy Revenue: Rs. 617 Cr. EBITDA Margin: 24% Revenue: Rs. 570 Cr. EBITDA Margin: 24% Revenue: Rs. 449 Cr. EBITDA Margin: 24% FY24 FY25 TTM FY30 47
Slide 53: Large Pharma strategy and Biosecure Act
Growth driver: • Add Large Pharma • Executing strategy on Large Pharma Proposed Biosecure Act • Footprint in EU • Act passed in Sep’24 by US House of Representatives • Introduction of ADCs, mAbs, and Biologics platforms • American pharma companies to look for alternatives besides China 48
Slide 54: Capacity expansion in Drug Discovery
Expansion at current sites, Greater Noida & Bengaluru Expansion at new site, Devanahalli, Bengaluru Capacity : 1,000 FTE’s ( FY25 ) 2,000 FTE’s ( FY28 ) 4,000 FTE’s ( FY30 ) Increasing capacity in a phased manner ; Total Capex USD 150 Mn. ( Expect RoCE > 20% ) 49
Slide 55: Integration of France R&D facility
• Expanded TAM by USD 1.4 Bn. in mAbs and ADCs • Added strategic footprint in the EU • Enhanced domain expertise in ADC • Unique & cost-effective delivery model Integration in progress; Investing in Business development team 50
Slide 56: CDMO API quarterly results
Particulars ( Rs. Cr.) Q1’FY25 Q4’FY25 Q1’FY26 Y-o-Y • Q1’Y26 revenue increased YoY on the back of increased volume in select products. Industry wide pricing pressure continues Revenue 130 182 141 9% • Q1’FY26 EBITDA margins increased YoY due to EBITDA 16 39 22 36% profitable product mix added by su
Slide 57: CDMO API FY30 targets
Revenue: Growth momentum 2x of FY24 is starting Margin improvement EBITDA Margin: on track More than 15% Revenue: Rs. 593 Cr. EBITDA Margin: 16% Revenue: Rs. 581 Cr. EBITDA Margin: 15% Revenue: Rs. 645 Cr. EBITDA Margin: 10% FY24 FY25 TTM FY30 52
Slide 58: Growing CDMO API; transfer to Jubilant Biosys
Growth driver: • Grow CDMO API • Further Strengthen CDMO: Leverage GMP manufacturing capabilities for Innovative New Chemical Entities • Custom Manufacturing: Partner with large pharma to manufacture products requiring life cycle management • China plus one strategy: Resilient supply chain through i
Slide 59: Generics
Generics
Slide 60: Generics Market Growth Drivers and Trends
Generics Market Growth Drivers and Trends USD Bn ~ 532 Developed Market 19 • US market to grow at 2%, signs of decrease in price reductions ~ 406 15 203 • Non-US market to grow by 5 - 7% 149 India Market 310 242 • India market to grow in excess of 8% • Brand building, in-clinic effectiveness of sale
Slide 61: Generics: Non-US, US and Indian markets
Non-US international market • Broad therapeutic coverage - CVS, CNS, GI and multi specialty • 1 key market with triple digit revenue in INR Cr., Build total of 3 - 4 markets (B2B2C) • Global presence in 50+ markets - US, Europe, Canada, Japan, Australia • CMO to few large branded generics customers
Slide 62: Generics quarterly results
Particulars ( Rs. Cr.) Q1’FY25 Q4’FY25 Q1’FY26 Y-o-Y • Q1’FY26 revenue increased YoY due to increase in revenue from Non-US markets Revenue 156 157 166 7% • Q1’FY26 EBITDA and EBITDA margins increased YoY due to focus on profitable EBITDA (11) (17) 12 214% products EBITDA Margin (%) (7%) (11%) 7% 1,
Slide 63: Generics FY30 targets
Revenue : Growth momentum ~2x of FY24 is starting EBITDA Margin : Margin improvement on track 15% to 17% Revenue : Rs. 696 Cr. EBITDA Margin : 7% Revenue : Rs. 685 Cr. Revenue : Rs. 775 Cr. EBITDA Margin : 3% EBITDA Margin : (18%) FY24 FY25 TTM FY30 58
Slide 64: Generics growth levers
Launch Grow the profitable Build branded new products Non-US international market business • Relaunch dormant ANDAs from • Launch 6 to 8 new products • Build presence in Diabetes, Roorkee and CMO network every year Dyslipidemia and Hypertension • Secure ANDAs approvals • Scale 3 to 4 key markets • S
Slide 65: Proprietary Novel Drugs
Proprietary Novel Drugs
Slide 66: Proprietary novel drugs approach
• Develop precision oral medicines with enhanced safety and therapeutic efficacy • Focused on specific set of patients, not responding to other therapies • Low-cost in-house discovery engine to generate drug candidates, validated through partnerships • Guided by world’s leading oncologists from Memo
Slide 67: JBI-802
• Company sponsored Phase II trial underway Blood Cancer • Highly differentiated for safety and efficacy than peers ET/MPN • Total Addressable Market in US: USD 3.3 Bn. • Investigator led trial initiated Lung Cancer JBI-802 NSCLC • Demonstrated clinical efficacy in two NSCLC patients in phase 1 stud
Slide 68: JBI-802 patient responses
• Non small cell lung cancer patient progressed to last stage after immunotherapy. Post taking JBI-802 treatment, patient has been doing very well even after two years. Major symptoms have disappeared with confirmed partial response with ~40% tumor reduction • Over 50% shrinkage of the patient’s liv
Slide 69: JBI-778
Lung Cancer • Total Addressable Market in US: USD 2.0 Bn. NSCLC with EGFR mutation Brain Tumor • High unmet need with no effective treatment option JBI-778 HGG • Total Addressable Market in US: USD 1.7 Bn. Phase I trial underway Head & Neck • Chemotherapy, current treatment option has low efficacy c
Slide 70: Proprietary Novel Drugs quarterly results
• Continue to invest in a calibrated manner in two Particulars ( Rs. Cr.) Q1’FY25 Q4’FY25 Q1’FY26 Y-o-Y lead programs Revenue 0 0 0 EBITDA (6) (4) (6) (3%) 65
Slide 71: Expected data readouts and monetization
• Expect clinical data readouts in CY 2026 • Explore monetization through licensing or external fund raising 66
Slide 72: Consolidated profit and loss
Particulars ( Rs. Cr. ) Q1’FY25 Q4’FY25 Q1’FY26 Y-o-Y • Q1’FY26 Revenue grew YoY on the back of growth in revenue across all business units Revenue 1,732 1,929 1,901 10% • Q1’FY26 EBITDA margins increased YoY due Other Income 14 12 12 to improved performance in CRDMO and Generics Total Income 1,746
Slide 73: Net debt and leverage
Particulars ( Rs. Cr. ) Mar 31, 2025 June 30, 2025 • Investing consciously to maintain Net debt / Ebitda range bound Net Debt ( On constant currency, Net of DIC ) 1,348 1,535 Net Debt / Equity 0.22 0.24 Net Debt / EBITDA (TTM) 1.1 1.2 Long Term Capex Creditors 453 455 Exchange Rate : 1 USD = INR 85.
Slide 74: Sustainability Performance
DJSI Score 60% EcoVadis Score 65 Winner – Mid/Small Cap Category B - Water Security, D - Climate Member since 2005 All Indian manufacturing plants are 19% reduction in Specific Water Zero Liquid Discharge Consumption v/s FY 25 target Sustainability CoP submitted, Performance Category I ERP 3rd July
Slide 75: Q1'FY26 business summary
Radio Pharmaceuticals : Ruby-Fill® maintaining growth momentum. New Products to drive margin expansion 1 Radio Pharmacies : Competitive intensity higher in SPECT, Commercial distribution of PLYARIFY® in PET continue to grow 2 Allergy Immunotherapy : Revenue grew YoY; EBITDA margins in normalized ran
Slide 76: Total income and EBITDA by segment
Total Income ( Rs. Cr. ) Q1’FY25 Q4’FY25 Q1’FY26 Revenue (A) 1,732 1,929 1,901 a. Radiopharma 832 895 869 Radiopharmaceuticals 262 296 271 Radiopharmacies 570 600 598 b. Allergy Immunotherapy 168 192 181 c. CDMO Sterile Injectables 324 340 370 d. CRDMO 243 338 302 Drug Discovery Services 113 156 161
Slide 77: Vision 2030 targets
Revenue Reach 2x from FY24 to FY30 EBITDA Margin 23% to 25% by FY30 Net Debt Zero by FY30 RoCE High Teens by FY30 72
Slide 78: Annexure
Annexure Arvind Chokhany Group CFO, Whole-time Director
Slide 79: Chairmen and senior management
Shyam S Bhartia Hari S Bhartia Priyavrat Bhartia Arjun S Bhartia Chairman Co-Chairman Managing Director Joint Managing Director Arvind Chokhany Shantanu Jha Dr Tushar Gupta Group CFO, Whole-time Director Group CHRO Head - Corporate Strategy 74
Slide 80: Business CEOs
Harsher Singh Chris Preti Giuliano Perfetti CEO - Jubilant Radiopharma CEO - CDMO Sterile Injectables CEO - CRDMO, Biosys Dr Jaidev Rajpal Kyle Ferguson Dr Syed Kazmi CEO - Jubilant Generics CEO - Allergy Immunotherapy CEO - Jubilant Therapeutics 75
Slide 81: Shareholding pattern
0.6% 24.8% Promoter and Promoter Group Domestic Institutions 47.7% Foreign Institutions Non - Institutions 17.4% Employee Benefit Trust 9.5% 76
Slide 82: Abbreviations
Abbreviation Details Abbreviation Details CVS Cardiovascular System MEA Middle East Africa CNS Central Nervous System LATAM Latin America CDMO Contract Development Manufacturing Organization LOE Loss of exclusivity CRDMO Contract Research & Development Manufacturing Organization FDA (US) U.S. Food a
Slide 83: Thanks!
Thanks!
Slide 84: Q1'FY26 Q&A / Disclaimer
Q1’FY26 Q&A Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and ta
Slide 85: Radiopharmaceuticals Q&A: Ruby-Fill
Radiopharmaceuticals Q1. Can you talk about growth in Ruby-Fill®? Answer: Ruby-fill® is a best in class Positron Emission Tomography (PET) radiopharmaceutical product used for Cardiac imaging through a non-invasive procedure of the myocardium, to evaluate regional myocardial perfusion in adult patie
Slide 86: Radiopharma pipeline and radiopharmacy Q&A
Answer: We have a very strong pipeline of products in PET and SPECT with an Addressable Market at approx. USD 550 million. These products are generics or 505 B(2) versions of existing products and will be launched from FY27 to FY29. In addition to that, on the therapeutics side, we are working on MI
Slide 87: Allergy Immunotherapy growth levers Q&A
Q8. What are the growth levers in this business? Answer: The business is moving ahead on a three-pronged growth strategy. The first is to strengthen the existing position in both Venom and Non-Venom segment in the US. We are increasing customer awareness about the importance of bee sting allergy tre
Slide 88: CDMO Sterile Injectables demand Q&A
The drug shortages in the injectables in the US are signalling that the demand still runs higher than the supply of the capacity and therefore there is a need of significant new capacity. In particular, a recent McKinsey report highlighted a 6.8Bn demand vs. 6.1Bn supply specifically for sterile via
Slide 89: Spokane and Montreal operations Q&A
injectables operations successfully in middle of Q3’FY25 and are stable now. We plan to return to production for ophthalmic line in H2’FY26. Also at the Montreal facility, we have announced an investment of USD 114 million towards the expansion of our liquid and lyophilization sterile fill operation
Slide 90: CRDMO Q&A
Answer: In Q1’FY26, the Drug Discovery business revenue grew by 42% to Rs. 161 Cr and EBITDA grew by 46% to Rs. 32 Cr. Q1’FY26 revenue increased YoY due to increase in revenue from large Pharma customers. We have integrated new R&D facility in France and are now investing in business development. EB
Slide 91: Generics and Novel Drugs Q&A
Answer: Since April’24, we secured approval of (9) ANDA’s from our pipeline and acquired (2) ANDAs. We plan to launch six to eight products per annum in our US and non-US international markets in the current year. Therefore, we have an improving growth and profitability outlook. In line with our com
Slide 92: Financials and FY26 outlook Q&A
Answer: In Q1’FY26, Revenue grew by 10% on a YoY basis to Rs. 1,901 Cr. on the back of growth in revenue across all business units. EBITDA grew by 14% on a YoY basis to Rs. 302 Cr. due to improved performance in CRDMO and Generics. Q1’FY26 normalised PAT increased by 48% on a YoY basis to Rs. 103 Cr